AZD4547 is a potent reversible TKI specific for FGFRs.713 Of note, AZD4547 is able to sharply diminish cancer stem-like cells by inducing MET via MEK/ERK pathway downstream of FGFR signaling.714 In addition, administered AZD4547 prominently impaired ductal branching and stem cell-like characteristics in mammary epithelial cell and spontaneous tumor cells.715 In phase I/II trials, AZD4547 further showed promising inhibitory activity in models of cancer with FGFR alteration. This evidence concerns the gene MET and cancer.